Glargine U300 Hospital Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 247 participants.

Also called NCT03013985

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 247 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03013985
Other papers using this trial's data
  • A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial Diabetes care, 2020-06 DOI, PubMed 32273271, PMC7411278 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03013985. Randomized; no masking; primary purpose treatment. Start 2017-05-17 (actual); primary completion 2019-03-22 (actual). Results posted on 2020-05-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glargine U300 Hospital Trial
Intervention (Drug)
Glargine U300
Intervention (Drug)
Glargine U100
Intervention (Drug)
Glulisine Insulin
Lead sponsor
Emory University (class: other)

Record details

Record id
cardio:ct-nct03013985
Content hash
958bcf0fda4594807a72d46138cb2e74a18e76af83ee6ad6382a5bafe4c61a3e